GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (WBO:NNO2) » Definitions » Peter Lynch Fair Value

Novo Nordisk AS (WBO:NNO2) Peter Lynch Fair Value : €63.93 (As of Dec. 15, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Novo Nordisk AS Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Novo Nordisk AS's PEG is 1. Novo Nordisk AS's 5-Year TTM EBITDA Growth Rate is 22.48. Novo Nordisk AS's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was €2.84. Therefore, the Peter Lynch Fair Value for today is €63.93.

As of today (2024-12-15), Novo Nordisk AS's share price is €100.40. Novo Nordisk AS's Peter Lynch fair value is €63.93. Therefore, Novo Nordisk AS's Price to Peter Lynch Fair Value Ratio for today is 1.57.


The historical rank and industry rank for Novo Nordisk AS's Peter Lynch Fair Value or its related term are showing as below:

WBO:NNO2' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.8   Med: 2.28   Max: 5.58
Current: 1.58


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Novo Nordisk AS was 5.58. The lowest was 0.80. And the median was 2.28.


WBO:NNO2's Price-to-Peter-Lynch-Fair-Value is ranked worse than
54.81% of 270 companies
in the Drug Manufacturers industry
Industry Median: 1.45 vs WBO:NNO2: 1.58

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Novo Nordisk AS Peter Lynch Fair Value Historical Data

The historical data trend for Novo Nordisk AS's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Peter Lynch Fair Value Chart

Novo Nordisk AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.14 8.14 8.85 17.68 40.69

Novo Nordisk AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.24 40.69 50.24 55.25 64.09

Competitive Comparison of Novo Nordisk AS's Peter Lynch Fair Value

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Price-to-Peter-Lynch-Fair-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Price-to-Peter-Lynch-Fair-Value falls into.



Novo Nordisk AS Peter Lynch Fair Value Calculation

Novo Nordisk AS's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 22.48 *2.844
=63.93

Novo Nordisk AS's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.84.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Novo Nordisk AS  (WBO:NNO2) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 22.48 instead of 15 in this case.

Novo Nordisk AS's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=100.40/63.93
=1.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk AS Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines